Blueshift Asset Management’s Neurocrine Biosciences NBIX Stock Holding History

Blueshift Asset Management’s Portfolio NBIX Stock Details NBIX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q4	–	Sell	-4,284	Closed	-$494K	–	464
2024 Q3	$494K	Buy	+4,284	New	+$587K	0.12%	196
2024 Q2	–	Sell	-2,705	Closed	-$373K	–	397
2024 Q1	$373K	Buy	+2,705	New	+$369K	0.19%	164
2023 Q3	–	Sell	-4,481	Closed	-$423K	–	378
2023 Q2	$423K	Buy	+4,481	New	+$438K	0.16%	157
2022 Q2	–	Sell	-2,654	Closed	-$249K	–	903
2022 Q1	$249K	Sell	2,654 -1,702	-39%	-$144K	0.02%	674
2021 Q4	$371K	Buy	+4,356	New	+$401K	0.03%	571
2021 Q2	–	Sell	-2,120	Closed	-$206K	–	1082
2021 Q1	$206K	Buy	+2,120	New	+$222K	0.02%	770
2019 Q3	–	Sell	-2,874	Closed	-$243K	–	874
2019 Q2	$243K	Buy	+2,874	New	+$236K	0.03%	609

Other funds holding NBIX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Blueshift Asset Management's NBIX Position: Q4 2024 in Review

Blueshift Asset Management sold out of Neurocrine Biosciences (NBIX) in Q4 2024, closing a stake of 4,284 shares — an estimated $494K sold.

Blueshift Asset Management first reported a position in NBIX in Q2 2019 and held it in 7 quarters. The position peaked at $494K in Q3 2024. 600 funds tracked by Wall St. Rank hold NBIX as of Q4 2024.

Blueshift Asset Management reported no remaining Neurocrine Biosciences position as of Q4 2024 after selling out during the quarter.
Blueshift Asset Management sold 4,284 Neurocrine Biosciences shares in Q4 2024, an estimated $494K.
Blueshift Asset Management first reported a position in Neurocrine Biosciences in Q2 2019 and held it in 7 quarters.
Blueshift Asset Management's Neurocrine Biosciences position peaked at $494K in Q3 2024.
600 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q4 2024.

Based on Blueshift Asset Management's 13F filing for Q4 2024, filed 11 Feb 2025.